

Daniel Aletaha

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8190186/daniel-aletaha-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210
papers

29,383
citations

63
h-index

171
g-index

257
ext. papers

36,586
ext. citations

5.2
avg, IF

7.21
L-index

#	Paper	IF	Citations
210	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2569-81		4825
209	2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1580-8	2.4	2158
208	Rheumatoid arthritis. <i>Lancet, The</i> , 2016 , 388, 2023-2038	40	1794
207	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	2.4	1649
206	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 492-503	2.4	1487
205	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 631-7	2.4	1300
204	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 964-75	2.4	1210
203	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699	2.4	851
202	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
201	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 18001	51.1	750
200	New therapies for treatment of rheumatoid arthritis. <i>Lancet, The</i> , 2007 , 370, 1861-74	40	706
199	Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. <i>Arthritis Research</i> , 2005 , 7, R796-806		640
198	Diagnosis and Management of Rheumatoid Arthritis: A Review. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1360-1372	27.4	596
197	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011 , 63, 573-86		520
196	American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 404-13	2.4	518
195	The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2005 , 23, S100-8	2.2	375
194	Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2625-36		337

193	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 3-17	2.4	320
192	Distinctions between diagnostic and classification criteria?. <i>Arthritis Care and Research</i> , 2015 , 67, 891-7	4.7	268
191	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 276-89	8.1	265
190	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 948-959	2.4	243
189	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 700-712	2.4	238
188	Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. <i>Circulation</i> , 2005 , 111, 204-11	16.7	238
187	Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2784-92		205
186	Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 811-8	2.4	202
185	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 328-35	2.4	182
184	Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1441-7	2.4	182
183	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2582-91		182
182	Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3226-35		181
181	Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2814-23		175
180	A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. <i>Rheumatology</i> , 2009 , 48, 1114-21	3.9	173
179	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 638-643	2.4	168
178	Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). <i>International Immunology</i> , 2008 , 20, 861-8	4.9	157
177	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 16-22	2.4	156
176	Proposal for a new nomenclature of disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 3-5	2.4	155

175	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 8-13	2.4	143
174	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 491-496	2.4	125
173	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1589-95	2.4	117
172	Minimal disease activity for rheumatoid arthritis: a preliminary definition. <i>Journal of Rheumatology</i> , 2005 , 32, 2016-24	4.1	116
171	Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 733-9	2.4	115
170	Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. <i>Arthritis and Rheumatism</i> , 2011 , 63, 43-52		110
169	Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 995-1003	2.4	108
168	The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007 , 21, 663-75	5.3	100
167	Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3702-11		99
166	Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1242-9		99
165	Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 687-93	2.4	94
164	Impact of comorbidity on physical function in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 536-41	2.4	90
163	Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on Specificity. <i>Clinical Chemistry</i> , 2020 , 66, 1405-1413	5.5	89
162	Comparative effectiveness and safety of biological treatment options after tumour necrosis factor inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1303-8	2.4	88
161	SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1345-1350	2.4	88
160	Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 114-23	2.4	87
159	The definition and measurement of disease modification in inflammatory rheumatic diseases. <i>Rheumatic Disease Clinics of North America</i> , 2006 , 32, 9-44, vii	2.4	87
158	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 479-81	2.4	85

157	Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. <i>Arthritis Research and Therapy</i> , 2014 , 16, R56	5.7	84
156	Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011 , 50, 381-8	3.9	81
155	Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1702-5	2.4	81
154	Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1058-64	2.4	79
153	Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. <i>Lancet, The</i> , 2017 , 389, 1206-1217	4.0	78
152	Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. <i>Journal of Rheumatology</i> , 2002 , 29, 1631-8	4.1	74
151	Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1284-8	2.4	72
150	The pathogenesis of rheumatoid arthritis: new insights from old clinical data?. <i>Nature Reviews Rheumatology</i> , 2012 , 8, 235-43	8.1	70
149	Anti-TNF in rheumatoid arthritis: an overview. <i>Wiener Medizinische Wochenschrift</i> , 2015 , 165, 3-9	2.9	65
148	Patient-reported outcomes in chronic gout: a report from OMERACT 10. <i>Journal of Rheumatology</i> , 2011 , 38, 1452-7	4.1	64
147	Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2975-83		63
146	SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1355-1356	2.4	63
145	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 31-35	2.4	61
144	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1999-2002	2.4	59
143	Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. <i>Rheumatology</i> , 2009 , 48, 1575-80	3.9	58
142	Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 238-43	2.4	58
141	Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 546-9	2.4	57
140	Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1190-6	2.4	56

139	The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?. <i>Arthritis Research and Therapy</i> , 2008 , 10, 208	5.7	56
138	Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 875-80	2.4	55
137	Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. <i>Clinical Reviews in Allergy and Immunology</i> , 2005 , 28, 239-48	12.3	55
136	Therapeutic strategies in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 163-77	5.3	55
135	Forget personalised medicine and focus on abating disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 3-6	2.4	54
134	Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2015 , 17, 229	5.7	51
133	Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2005-14		50
132	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 71-87	2.4	50
131	Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1631-40	2.4	48
130	Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1479-85	2.4	47
129	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1705-1709	2.4	45
128	Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. <i>Arthritis and Rheumatology</i> , 2014 , 66, 794-802	9.5	43
127	Rheumatoid arthritis and falls: the influence of disease activity. <i>Rheumatology</i> , 2012 , 51, 2051-7	3.9	43
126	Developments in the clinical understanding of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009 , 11, 204	5.7	43
125	Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1975-80	2.4	42
124	Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1269-75	2.4	40
123	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 45, 167-73	5.3	39
122	Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. <i>Rheumatology</i> , 2015 , 54, 994-1007	3.9	39

121	The importance of reporting disease activity states in rheumatoid arthritis clinical trials. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2622-31		39
120	The need for new classification criteria for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3333-6		37
119	Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 575-8	2.4	36
118	The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care. <i>Rheumatic Disease Clinics of North America</i> , 2009 , 35, 759-72, viii	2.4	35
117	Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents. <i>BMC Musculoskeletal Disorders</i> , 2009 , 10, 41	2.8	33
116	Fever of unknown origin (FUO) revised. <i>Wiener Klinische Wochenschrift</i> , 2016 , 128, 796-801	2.3	33
115	Risk profiling for a refractory course of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 211-217	5.3	32
114	Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 241-4	2.4	31
113	Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. <i>Arthritis and Rheumatology</i> , 2017 , 69, 728-734	9.5	29
112	Remission by composite scores in rheumatoid arthritis: are ankles and feet important?. <i>Arthritis Research and Therapy</i> , 2007 , 9, R72	5.7	28
111	Therapeutic implications of autoantibodies in rheumatoid arthritis. <i>RMD Open</i> , 2016 , 2, e000009	5.9	28
110	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 963-9	2.4	27
109	Activity assessments in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2008 , 20, 306-13	5.3	27
108	Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S48-50	2.2	27
107	An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets. <i>Wiener Klinische Wochenschrift</i> , 2016 , 128, 791-795	2.3	25
106	Early rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2006 , 18, 282-8	5.3	25
105	Monitoring rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011 , 23, 252-8	5.3	24
104	The effects of structural damage on functional disability in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 2038-2045	2.4	23

103	Precision medicine and management of rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2020 , 110, 102405-55	5.5	22
102	Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 633-634	8.1	22
101	Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. <i>Vaccine</i> , 2018 , 36, 4875-4879	4.1	21
100	Cardiovascular risk factors and comorbidities in patients with hyperuricemia and/or gout: a systematic review of the literature. <i>Journal of rheumatology Supplement, The</i> , 2014 , 92, 9-14		20
99	Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015 , 17, 203	5.7	20
98	Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study. <i>Advances in Therapy</i> , 2019 , 36, 1672-1683	4.1	19
97	Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 7-12	2.4	19
96	Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1609-1615	2.4	19
95	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. <i>Rheumatology</i> , 2017 , 56, 689-697	3.9	18
94	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 445-452	2.4	17
93	Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for Psoriatic Arthritis (DAPSA) based on 28 joints?. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1736-1741	2.4	17
92	Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. <i>Rheumatology</i> , 2020 , 59, 324-334	3.9	16
91	Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020 , 15, e0233781	3.7	15
90	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018 , 20, 174	5.7	15
89	Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity		15
88	Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points. <i>Arthritis and Rheumatology</i> , 2017 , 69, 518-528	9.5	13
87	Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , 2017 , 69, 720-727	9.5	12
86	Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis. <i>Journal of Autoimmunity</i> , 2020 , 108, 102379	15.5	12

85	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 276-284	5.3	12
84	Compression test (Gaenslen's squeeze test) positivity, joint tenderness, and disease activity in patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2013 , 65, 653-7	4.7	11
83	The American College of Rheumatology N (ACR-N) debate: going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers. <i>Arthritis and Rheumatism</i> , 2006 , 54, 377-8; author reply 378		11
82	2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	11
81	Clinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 193-198	5.3	10
80	The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. <i>Rheumatology</i> , 2019 , 58, 2091-2098	3.9	10
79	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1755-60	2.4	10
78	Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind?. <i>Arthritis Research and Therapy</i> , 2006 , 8, 102	5.7	10
77	Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	10
76	Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e67	2.4	9
75	Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 874-882	2.4	9
74	Reliability of patient-reported outcomes in rheumatoid arthritis patients: an observational prospective study. <i>Rheumatology</i> , 2016 , 55, 41-8	3.9	9
73	Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns. <i>PLoS ONE</i> , 2019 , 14, e0219698	3.7	9
72	Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 532-7	2.4	9
71	Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 245-251	5.3	8
70	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , 2018 , 4, e000756	5.9	8
69	EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , 2018 , 4, e000780	5.9	8
68	Disease activity assessment in patients with psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 401-414	5.3	8

67	Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. <i>Rheumatology and Therapy</i> , 2021 , 8, 1519-1534	4.4	8
66	The use of data from early arthritis clinics for clinical research. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009 , 23, 117-23	5.3	7
65	Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data. <i>Arthritis Research and Therapy</i> , 2009 , 11, 112	5.7	7
64	Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics. <i>Current Rheumatology Reports</i> , 2003 , 5, 409-12	4.9	7
63	Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. <i>RMD Open</i> , 2020 , 6,	5.9	7
62	Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years. <i>Rheumatology</i> , 2020 , 59, 1556-1565	3.9	7
61	Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial		7
60	Information technology concerning SDAI and CDAI. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, S45-S48	2.2	7
59	New insights into the measurement of disease activity in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 268-72	5.3	6
58	Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiative. <i>Journal of rheumatology Supplement, The</i> , 2011 , 87, 54-8		6
57	Pre-arthritis: a concept whose time has come. <i>Future Rheumatology</i> , 2006 , 1, 1-4		6
56	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	6
55	EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1286-1298	2.4	6
54	Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor- β inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. <i>ClinicoEconomics and Outcomes Research</i> , 2017 , 9, 451-458	1.7	5
53	The EULAR points to consider for health professionals undertaking musculoskeletal ultrasound for rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 311-313	2.4	5
52	Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	5
51	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020 , 59, 1842-1852	3.9	5
50	Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 884-890	2.4	5

49	Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. <i>RMD Open</i> , 2018 , 4, e000773 ⁵⁹	5.9	5
48	Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients. <i>Rheumatology</i> , 2018 , 57, 969-976	3.9	4
47	The sensitivity improved two-test algorithm BIT2 is a universal optimization strategy for SARS-CoV-2 serology		4
46	The many faces of psoriatic arthritis - a challenge to treatment to target?. <i>Reumatologia</i> , 2016 , 54, 1-2	1.7	4
45	Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. <i>Rheumatology</i> , 2019 , 58, 1025-1033	3.9	4
44	A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	4
43	Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	4
42	Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study. <i>Patient Preference and Adherence</i> , 2020 , 14, 949-961	2.4	3
41	To DAPSA or not to DAPSA? That is not the question. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e61	2.4	3
40	A critical review of the reproductive safety of Leflunomide. <i>Clinical Rheumatology</i> , 2020 , 39, 607-612	3.9	3
39	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021 , 20, 102849	13.6	3
38	Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials. <i>Journal of Rheumatology</i> , 2016 , 43, 1024-6	4.1	3
37	Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology. <i>Nature Medicine</i> , 2020 , 26, 974-980	50.5	3
36	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 643-644	5.3	2
35	Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	2
34	Genetic risk scores in inflammatory arthritis: a new era?. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 545-548.	1	2
33	Pseudoerosions of Hands and Feet in Rheumatoid Arthritis: Anatomic Concepts and Redefinition. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	2
32	Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. <i>Rheumatology</i> , 2021 , 60, 682-691	3.9	2

31	Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. <i>RMD Open</i> , 2021 , 7,	5.9	2
30	Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e167	2.4	2
29	In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora. <i>RMD Open</i> , 2021 , 7,	5.9	2
28	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS.. <i>Arthritis and Rheumatology</i> , 2022 ,	9.5	2
27	Response to: 'Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis' by Bugatti. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1
26	Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1227-1229	9.5	1
25	Management of rheumatoid arthritis: what happens and what does not happen in real life. <i>Rheumatology International</i> , 2016 , 36, 167-8	3.6	1
24	Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 315-324	2.4	1
23	Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2019 , 21, 231	5.7	1
22	The health assessment questionnaire in routine clinical practice. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 122-3		1
21	Classification of rheumatoid arthritis 2015 , 3-21		1
20	Evaluation and outcomes of patients with rheumatoid arthritis 2015 , 790-801		1
19	Outcome Measurement in Rheumatoid Arthritis: Disease Activity 2009 , 225-230		1
18	Evaluation and outcomes of patients with rheumatoid arthritis 2011 , 941-954.e1		1
17	Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'' by Westhoff. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e163	2.4	1
16	Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211022533	3.8	1
15	Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). <i>RMD Open</i> , 2021 , 7,	5.9	1
14	Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20933489	3.8	0

13	The 2021 EULAR and ACR points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	○
12	Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e54	2.4	○
11	Targeting p19 in psoriatic arthritis: more than just another therapeutic approach?. <i>Lancet, The</i> , 2020 , 395, 1091-1093	4.0	
10	Reply: To PMID 24757132. <i>Arthritis and Rheumatology</i> , 2014 , 66, 3245-6	9.5	
9	How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients. <i>BioDrugs</i> , 2014 , 28 Suppl 1, S3-4	7.9	
8	Is computer-assisted management necessary for patients with early rheumatoid arthritis?. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 338-9		
7	Monitoring disease activity in rheumatoid arthritis: an imperative. <i>Future Rheumatology</i> , 2008 , 3, 99-102		
6	Reply to "Correspondence on "Re-examining remission definitions in RA: considering the DAS28, CRP level and patient global assessment" by Felson et al.". <i>Arthritis Care and Research</i> , 2021 ,	4.7	
5	Reply.. <i>ACR Open Rheumatology</i> , 2022 ,	3.5	
4	Response to: 'Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab" by Pethoe-Schramm. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	
3	Response to: 'Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis" by Dumoulin. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	
2	Message from the new EULAR President and Steering Group. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1266-1267	2.4	
1	Response to: Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment' by Felson .. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	